Cabaletta Bio (CABA) insider buying

Healthcare · Biotechnology · Market cap $290M

7 open-market purchases of CABA by Cabaletta Bio's executives and directors since January 2026, worth $286,211 in total, from SEC Form 4 filings.

The most recent: Mark Simon bought $25,219 on January 21, 2026.

The biggest buyer over the period is Steven Nichtberger: 1 purchase, $100,800.

By year

YearPurchasesValue
20267$286,211

Biggest buyers

InsiderBuysValue
Steven Nichtberger
1$100,800
Steve Gavel
1$50,326
Shawn Tomasello
1$50,222
Mark Simon
1$25,219
Gwendolyn Binder
1$24,773
David J Chang
1$19,888
Michael Gerard
1$14,982

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Jan 21, 2026 Mark Simon
11,061$2.28$25,219 Form 4
Jan 21, 2026 David J Chang
8,800$2.26$19,888 Form 4
Jan 21, 2026 Gwendolyn Binder
11,312$2.19$24,773 Form 4
Jan 21, 2026 Michael Gerard
6,600$2.27$14,982 Form 4
Jan 21, 2026 Shawn Tomasello
22,725$2.21$50,222 Form 4
Jan 21, 2026 Steve Gavel
22,170$2.27$50,326 Form 4
Jan 21, 2026 Steven Nichtberger
45,000$2.24$100,800 Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CABA.
Open CABA in Investingly

Questions

Are Cabaletta Bio insiders buying the stock?

7 open-market purchases of CABA by Cabaletta Bio's executives and directors since January 2026, worth $286,211 in total, from SEC Form 4 filings. The most recent: Mark Simon bought $25,219 on January 21, 2026.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Cabaletta Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.